SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s SG&A?
- Amneal Pharmaceuticals, Inc. (AMRX) reported SG&A of $138.86M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s SG&A increased by 17.4% year-over-year, from $118.29M to $138.86M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s SG&A has grown at a 9.6% compound annual growth rate (CAGR), from $365.5M to $526.83M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.